Belgian biotech company Vésale Bioscience has officially rebranded as Inteliphage, marking a strategic evolution in its mission and scope.
The company, known for its work in bacteriophage research, states that (On their LinkedIn page) the name change reflects its transition from a research-oriented organisation to one focused on delivering phage-based therapies for clinical use. According to the company, the goal is to support healthcare professionals with more precise, adaptable, and accessible solutions to tackle persistent and drug-resistant bacterial infections.
“Inteliphage” combines the concepts of intelligent therapy and phages — viruses that specifically target bacteria. The company describes its approach as using phages, either alone or in combination with antibiotics, to deliver targeted treatments based on evolving clinical evidence.
The company’s updated mission focuses on advancing phage therapy into routine care, aiming to provide scalable and effective alternatives in the face of rising antimicrobial resistance (AMR). Inteliphage states that it is building global partnerships with hospitals, researchers, and industry to accelerate the adoption of these treatments worldwide.
The announcement closed with a message of gratitude to past supporters and an invitation to join in the next phase of the company’s development.
For more information, visit the Inteliphage webpage.
